NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals (NASDAQ:DRNA) posted its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.57. The biopharmaceutical company earned $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

7 analysts have issued 12-month target prices for Dicerna Pharmaceuticals' shares. Their predictions range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $14.20 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.

Some companies that are related to Dicerna Pharmaceuticals include Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY) and Insmed (INSM).

Press coverage about DRNA stock has been trending somewhat positive recently, Accern reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $13.93.

Dicerna Pharmaceuticals has a market capitalization of $726.30 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]